Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

Summary

The purpose of this study is to evaluate the efficacy and safety of suzetrigine for acute pain after a bunionectomy.

Timeline

Start

2022-10-03

Primary completion

2023-12-15

Completion

2023-12-15

Outcome

Met primary endpoint

registry analysis (superiority test); Placebo vs Suzetrigine (SUZ); p = 0.0002; ANCOVA NCT05553366 ↗

release “Treatment with VX-548 following abdominoplasty or bunionectomy surgery resulted in a statistically significant improvement on the primary endpoint of the time-weighted sum of the pain” vrtx.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Acetaminophen	Small molecule	325 mg	Oral
Comparator	Hydrocodone bitartrate	Unknown	5 mg	Oral
Subject	Suzetrigine	Small molecule	50 mg	Oral

Indications

No indication recorded.